Payment overview · 2025
General Payments
$887.98
53 reported records · 14 companies
Healthcare provider profile · identity verified
Michael Samuel Mullins, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1457390734
Verified facts
What the public records show
CMS Open Payments records show Michael Samuel Mullins, MD received $887.98 in general payments during 2025 across 53 reported records.
ABBVIE INC. accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Xarelto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $267.51 | 30.1% | 19 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $139.62 | 15.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.78 | 10.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $76.55 | 8.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.03 | 8.3% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.32 | 4.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $35.37 | 4.0% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $33.88 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.59 | 3.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.57 | 2.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.93 | 2.5% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.48 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.31 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.04 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $887.98 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $161.97 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $139.62 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $105.54 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.03 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $74.03 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.53 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.29 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.32 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $42.32 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $35.37 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $33.88 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 86 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 648 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 517 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 81 |
| Omeprazole | Omeprazole | 304 | 83 |
| Lisinopril | Lisinopril | 280 | 70 |
| Gabapentin | Gabapentin | 277 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 243 | 80 |
| Donepezil Hcl | Donepezil Hcl | 243 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 242 | 47 |
| Montelukast Sodium | Montelukast Sodium | 238 | 55 |
| Metformin Hcl | Metformin Hcl | 229 | 56 |
| Trazodone Hcl | Trazodone Hcl | 219 | 37 |
| Buspirone Hcl | Buspirone Hcl | 215 | 49 |
| Potassium Chloride | Potassium Chloride | 214 | 48 |
| Losartan Potassium | Losartan Potassium | 210 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 195 | 56 |
| Meloxicam | Meloxicam | 188 | 57 |
| Furosemide | Furosemide | 176 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 42 |
| Prednisone | Prednisone | 150 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 29 |
| Clonazepam | Clonazepam | 108 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 15 |
| Farxiga | Dapagliflozin Propanediol | 86 | 13 |
| Lorazepam | Lorazepam | 85 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 15 |
| Sertraline Hcl | Sertraline Hcl | 82 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 16 |
| Allopurinol | Allopurinol | 73 | 19 |
| Famotidine | Famotidine | 73 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 23 |
| Warfarin Sodium | Warfarin Sodium | 66 | suppressed |
| Gemfibrozil | Gemfibrozil | 61 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 18 |
| Eliquis | Apixaban | 59 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 58 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 11 |
| Ezetimibe | Ezetimibe | 55 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 11 |
| Bupropion Xl | Bupropion Hcl | 52 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 11 |
| Tramadol Hcl | Tramadol Hcl | 50 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 18 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 12 |
| Ozempic | Semaglutide | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Atomoxetine Hcl | Atomoxetine Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 14 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Primidone | Primidone | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | 11 |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $887.98 · 53 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CARDIOMEMS, COMIRNATY, DUPIXENT, FANAPT, FARXIGA, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XYOSTED, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error